Dashboard
Manage Tickers

AZNASTRAZENECA PLC

Nasdaq astrazeneca.com


$ 78.72 $ 0.65 (0.83 %)    

Friday, 19-Jul-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 475.02 $ -4.25 (-0.89 %)
DIA $ 402.92 $ -3.77 (-0.93 %)
SPY $ 548.99 $ -3.67 (-0.66 %)
TLT $ 92.97 $ -0.55 (-0.59 %)
GLD $ 221.79 $ -4.05 (-1.79 %)
$ 78.71
$ 78.34
$ 78.70 x 200
$ 78.73 x 400
$ 78.19 - $ 78.76
$ 59.55 - $ 80.86
2,929,899
na
122.95B
$ 0.55
$ 7.19
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

european-commission-faces-court-criticism-over-covid-vaccine-contract-transparency-ahead-of-vote-on-ursula-von-der-leyens-reappointment
European Commission Faces Court Criticism ...
07/17/2024 18:24:05

European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implication...

uks-mhra-says-capivasertib-approved-to-treat-patients-with-advanced-breast-cancer
UK's MHRA Says Capivasertib Approved To Tr...
07/17/2024 14:50:51

- Reuters 

health-canada-approves-tagrisso-with-the-addition-of-chemotherapy-for-patients-with-egfr-mutated-advanced-lung-cancer
Health Canada Approves Tagrisso With The A...
07/12/2024 12:06:48

- Reuters

united-kingdom-stocks-etfs-to-watch-after-keir-starmer-labour-party-win
United Kingdom Stocks, ETFs To Watch After...
07/05/2024 16:53:39

New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying afte...

the-european-commission-approves-astrazenecas-tagrisso-osimertinib-with-pemetrexed-and-platinum-based-chemotherapy-as-1st-line-treatment-for-advanced-egfr-mutated-non-small-cell-lung-cancer-whose-tumors-have-exon-19-deletions-or-exon-21-mutations
The European Commission Approves AstraZene...
07/05/2024 10:33:10

astrazenecas-covid-19-prevention-drug-for-patients-with-weak-immune-systems---european-medicines-agency-accepts-marketing-application-under-accelerated-assessment
AstraZeneca's COVID-19 Prevention Drug For...
07/01/2024 16:43:08

The European Medicines Agency has accepted AstraZeneca's marketing authorization application for sipavibart, an investigati...

astrazenecas-imfinzi-durvalumab-and-lynparza-olaparib-have-been-recommended-for-approval-in-the-european-union-as-treatment-for-certain-patients-with-primary-advanced-or-recurrent-endometrial-cancer
AstraZeneca's Imfinzi (Durvalumab) And Lyn...
07/01/2024 10:04:13

Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been recommended for patients with misma...

astrazenecas-marketing-authorization-application-for-sipavibart-has-been-accepted-under-an-accelerated-assessment-procedure-by-the-european-medicines-agency-for-the-pre-exposure-prophylaxis-prevention-of-covid-19-in-immunocompromised-patients
AstraZeneca's Marketing Authorization Appl...
07/01/2024 09:49:26

china-approves-astrazenecas-tagrisso-chemotherapy-combo-regime-for-previously-untreated-lung-cancer-patients
China Approves AstraZeneca's Tagrisso-Chem...
06/26/2024 14:08:24

China has approved AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy for first-...

china-approves-astrazenecas-tagrisso-osimertinib-with-the-addition-of-pemetrexed-and-platinum-based-chemotherapy-for-the-first-line-treatment-of-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer
China Approves AstraZeneca's Tagrisso (Osi...
06/26/2024 08:56:41

astrazenecas-blockbuster-cancer-drug-imfinzi-flunks-as-follow-up-in-type-of-early-stage-lung-cancer-but-hits-primary-goal-in-phase-3-bladder-cancer-study
AstraZeneca's Blockbuster Cancer Drug Imfi...
06/25/2024 13:45:05

AstraZeneca's ADJUVANT BR.31 Phase 3 trial reveals Imfinzi didn't meet the primary endpoint for disease-free survival i...

japan-approves-astrazenecas-tagrisso-osimertinib-with-addition-of-pemetrexed-and-platinum-based-chemotherapy-as-new-first-line-treatment-for-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer
Japan Approves AstraZeneca's Tagrisso (Osi...
06/25/2024 09:04:56

astrazenecas-high-level-results-from-adjuvant-br31-phase-3-trial-of-imfinzi-did-not-achieve-statistical-significance-for-primary-endpoint-of-disease-free-survival-versus-placebo-in-early-stage-non-small-cell-lung-cancer
AstraZeneca's High-level Results From ADJU...
06/25/2024 09:02:36

astrazenecas-niagara-phase-3-trial-of-imfinzi-durvalumab-plus-chemotherapy-showed-statistically-significant-and-clinically-meaningful-improvement-in-event-free-survival-and-overall-survival-vs-neoadjuvant-chemotherapy-in-muscle-invasive-bladder-cancer
AstraZeneca's NIAGARA Phase 3 Trial Of Imf...
06/25/2024 08:59:42

supreme-court-backs-pharmaceutical-giants-in-iraq-terrorism-funding-case
Supreme Court Backs Pharmaceutical Giants ...
06/24/2024 19:47:37

The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment
Covid-19 Pharma Stars Continue Their Quest...
06/18/2024 14:19:12

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

astrazenecas-combination-cancer-drug-for-advanced-breast-cancer-study-flunks-late-stage-trial
AstraZeneca's Combination Cancer Drug For ...
06/18/2024 13:22:47

AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or me...

astrazenecas-capitello-phase-3-trial-for-truqap-capivasertib-combined-with-paclitaxel-in-locally-advancedmetastatic-triple-negative-breast-cancer-did-not-meet-the-dual-primary-endpoints-of-improvement-in-overall-survival-versus-paclitaxel-plus-placebo
AstraZeneca's CAPItello Phase 3 Trial For ...
06/18/2024 08:53:13

whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday
What's Going On With Small-Cap Cancer Focu...
06/17/2024 15:47:08

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)